Sugi Predict

Sugi Predict / Targets / FERMT2

FERMT2

Fermitin family homolog 2 · Q96AC1 · FERMT2 on Sugi Atlas →

4,201 patent compounds predicted against FERMT2, 3,211 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1147519 SCHEMBL1147519 1.00 7/20
SCHEMBL2328345 SCHEMBL2328345 0.51 7/20
SCHEMBL5549300 SCHEMBL5549300 0.68 6/20
SCHEMBL1073682 SCHEMBL1073682 0.64 6/20
SCHEMBL6698838 SCHEMBL6698838 1.00 5/20
SCHEMBL5071083 SCHEMBL5071083 0.52 5/20
SCHEMBL2999439 SCHEMBL2999439 0.44 5/20
SCHEMBL1147310 SCHEMBL1147310 1.00 4/20
SCHEMBL1147513 SCHEMBL1147513 1.00 4/20
SCHEMBL4278808 SCHEMBL4278808 1.00 4/20
SCHEMBL1147524 SCHEMBL1147524 0.97 4/20
SCHEMBL1147597 SCHEMBL1147597 0.97 4/20
SCHEMBL4281985 SCHEMBL4281985 0.85 4/20
SCHEMBL1147366 SCHEMBL1147366 0.77 4/20
SCHEMBL2528053 SCHEMBL2528053 0.75 4/20
SCHEMBL1147619 SCHEMBL1147619 0.74 4/20
SCHEMBL1855080 SCHEMBL1855080 0.74 4/20
SCHEMBL1860839 SCHEMBL1860839 0.74 4/20
SCHEMBL2489005 SCHEMBL2489005 0.74 4/20
SCHEMBL2944493 SCHEMBL2944493 0.74 4/20

Clinical trials — most relevant to FERMT2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Treatment of Ectopic Calcification in Fahr's Disease or Syndrome PHASE2RECRUITING
68 Gallium-Fibroblast Activating Protein Inhibitors-46 Positron Emission Tomography - Computerized Tomography for Molecular Assessment of Fibroblast Activation and Risk Assessment in Solid Tumors PHASE2UNKNOWN
Genetic Analysis of Fraser Syndrome and Fryns Syndrome nanCOMPLETED
FGL2/Fibroleukin and Hepatitis C Virus Recurrence Post Liver Transplantation nanUNKNOWN
Markers and Mechanisms of Macrovascular Disease in IDDM nanCOMPLETED
Genetic Analysis of Hereditary Disorders of Hearing and Balance nanCOMPLETED
Genetics of Fibromyalgia nanUNKNOWN
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders nanRECRUITING
Application of Linkage Analysis in the Identification of Novel Hereditary Factors in Familial Aneurysms nanACTIVE_NOT_RECRUITING
Muscle Tissue Bank for Muscular Dystrophy nanCOMPLETED
Family Myopia Study nanCOMPLETED
Genetic Education in BRCA Families nanENROLLING_BY_INVITATION
Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and Others nanRECRUITING
Molecular Studies on Hereditary Haemorrhagic Telangiectasia Families nanRECRUITING
Role of Genetics in Idiopathic Pulmonary Fibrosis (IPF) nanUNKNOWN
Neuralized1 and RGS14 Genes nanCOMPLETED
Genetic Markers for Focal Segmental Glomerulosclerosis nanCOMPLETED
Retrospective Analysis of Patients With Metastatic Renal Cell Carcinoma Treated With CABOzantinib nanRECRUITING
Identification of New Genes Implicated in Rare Neurosensory Diseases by Whole Exome Sequencing nanUNKNOWN
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives nanUNKNOWN
The Influence of Genetic Predisposition on Outcome After Catheter Ablation of Atrial Fibrillation. nanUNKNOWN
Familial Partial Lipodystrophy Study nanCOMPLETED
Transcranial Magnetic Stimulation (TMS) Studies of Dystonia nanCOMPLETED
Signs and Symptoms of Genetic Abnormalities Linked to Inherited Heart Disease nanCOMPLETED
Family Blood Pressure Program - GenNet Network nanCOMPLETED
Signs and Symptoms Associated With Molecular Defects in Genetically Inherited Heart Disease nanCOMPLETED
Exome Analysis in Hearing Impaired Patients nanUNKNOWN
Molecular Analysis of Patients With Neuromuscular Disease nanRECRUITING
Whole Exome and Whole Genome Sequencing for Genotyping of Inherited and Congenital Eye Conditions nanRECRUITING
Genetic Analysis of Inherited Urologic Malignant Disorders: Collection of Samples nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a FERMT2 binder may also engage these)

ProteinNameSimilarity
Q8CIB5 — 1.000 Q8CIB5 →
F1Q8X5 — 0.997 F1Q8X5 →
Q9W6S3 — 0.980 Q9W6S3 →
Q6QD73 — 0.979 Q6QD73 →
Q32LP0 — 0.977 Q32LP0 →
A2VDU2 — 0.977 A2VDU2 →
Q8BHL5 — 0.977 Q8BHL5 →
Q8BKH7 — 0.974 Q8BKH7 →
Q5RCW6 — 0.974 Q5RCW6 →
Q5RCC1 — 0.973 Q5RCC1 →
Q5RDV5 — 0.973 Q5RDV5 →
Q96JJ3 — 0.972 Q96JJ3 →
Q5ZJ17 — 0.972 Q5ZJ17 →
Q6NRD0 — 0.970 Q6NRD0 →
Q8BIK4 — 0.970 Q8BIK4 →
Q9BZ29 — 0.969 Q9BZ29 →
Q8K3H0 — 0.969 Q8K3H0 →
PRKD1 Serine/threonine-protein kinase D1 0.969 landscape →
MAPKAP1 Target of rapamycin complex 2 subunit MAPKAP1 0.968 landscape →
Q9NSN8 — 0.968 Q9NSN8 →
Q8N960 — 0.968 Q8N960 →
Q6AYF1 — 0.967 Q6AYF1 →
Q8K1B8 — 0.967 Q8K1B8 →
A6H6A9 — 0.966 A6H6A9 →
Q5R372 — 0.966 Q5R372 →
Q7SXV1 — 0.966 Q7SXV1 →
Q925E1 — 0.966 Q925E1 →
P48553 — 0.965 P48553 →
Q8N6S4 — 0.965 Q8N6S4 →
Q15413 — 0.965 Q15413 →